Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nabi Biopharmaceuticals has initiated its phase II proof-of-concept trial for Civacir for the prevention of hepatitis C-related liver disease after liver transplantation.
Subscribe to our email newsletter
Currently, there are no marketed therapies specifically indicated for prevention of re-infection post-liver transplant in HCV-positive patients.
Nabi Biopharmaceuticals is co-developing Civacir with Italian biopharmaceutical company Kedrion. Kedrion is fully funding the costs of the trials and is also funding some of the costs of manufacturing Civacir. The two companies will pursue a common strategy to develop and commercialize Civacir in Europe and the US, with Kedrion being Nabi Biopharmaceuticals' exclusive licensee to commercialize Civacir in Europe. In addition, Kedrion will pay milestone and royalty payments to Nabi Biopharmaceuticals.
“Civacir is uniquely positioned to fill a critical gap in the care of liver transplant patients by preventing re-infection with hepatitis C during a period after surgery when other therapies cannot be used,” said Thomas McLain, chairman, CEO and president, Nabi Biopharmaceuticals.
“Through our strategic partnership, we expect to conduct this and future clinical trials for Civacir in a way that is faster and at the same time much less costly for Nabi Biopharmaceuticals.”